Zymeworks (ZYME) Alert: Johnson Fistel Announces Investigation of Zymeworks Inc.; Encourages Investors to Contact the Firm for Additional Information

Friday, December 15, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN DIEGO, Dec. 15, 2017 /PRNewswire/ -- Johnson Fistel, LLP, is investigating potential violations of the federal securities

laws by Zymeworks Inc. (NYSE: ZYME) ("Zymeworks") and certain of its officers and directors. Zymeworks is a technology platform biotech company with a focus primarily on cancer drug development.  Zymeworks develops protein therapeutics for the
treatment of cancer based upon the Company's molecular modeling software for optimizing protein structure.

On April 28, 2017, Zymeworks sold 4.5 million shares of stock in its initial public stock offering (the "IPO"), raising $58.50 million in new capital.  However, since the IPO, Zymeworks stock has imploded, on December 14, 2017, the stock closed at $8.13.

Specifically, Johnson Fistel's investigation seeks to determine whether the Company's filings with the U.S. Securities and Exchange Commission in connection with its April 2017 initial public stock offering (the "IPO") contained untrue statements of material facts or omitted to state other facts necessary to make the statements made therein not misleading concerning the Company's clinical trials, business and operations.

If you have information that could assist in this investigation, or if you are a Zymeworks shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

About Johnson Fistel, LLP:Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:Johnson Fistel, LLPJim Baker, 619-814-4471  jimb@johnsonfistel.com

Cision View original content:http://www.prnewswire.com/news-releases/zymeworks-zyme-alert-johnson-fistel-announces-investigation-of-zymeworks-inc-encourages-investors-to-contact-the-firm-for-additional-information-300571966.html

SOURCE Johnson Fistel, LLP

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store